These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 28526081)

  • 41. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
    Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
    Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing.
    Ng PS; Wen WX; Fadlullah MZ; Yoon SY; Lee SY; Thong MK; Yip CH; Mohd Taib NA; Teo SH
    Clin Genet; 2016 Oct; 90(4):315-23. PubMed ID: 26757417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
    Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
    Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
    Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing.
    Rosenthal SH; Sun W; Zhang K; Liu Y; Nguyen Q; Gerasimova A; Nery C; Cheng L; Castonguay C; Hiller E; Li J; Elzinga C; Wolfson D; Smolgovsky A; Chen R; Buller-Burckle A; Catanese J; Grupe A; Lacbawan F; Owen R
    Biomed Res Int; 2020; 2020():3289023. PubMed ID: 32090079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germline mutation in the TP53 gene in uveal melanoma.
    Hajkova N; Hojny J; Nemejcova K; Dundr P; Ulrych J; Jirsova K; Glezgova J; Ticha I
    Sci Rep; 2018 May; 8(1):7618. PubMed ID: 29769598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ancestry-specific predisposing germline variants in cancer.
    Oak N; Cherniack AD; Mashl RJ; ; Hirsch FR; Ding L; Beroukhim R; Gümüş ZH; Plon SE; Huang KL
    Genome Med; 2020 May; 12(1):51. PubMed ID: 32471518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
    Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.